Table 1.
Patients | Sex/Age | Tumor Size (cm) | Hormonal Pattern* | Time of Follow-up (mo) | No. CNA (Gain/Loss) | No. cnLOH |
1 (350A) | F/35 | 1.5 | Subclinical | 47 | 284 (30/254) | 0 |
2 (802A) | F/55 | 6.5 | Overt | 29 | 237 (229/8) | 0 |
3 (283A) | F/43 | 2.8 | Subclinical | 61 | 148 (148/0) | 2 |
4 (312A) | M/71 | 11.0 | Overt | 60 | 123 (24/99) | 1 |
5 (474A) | F/42 | 1.8 | Overt | 39 | 46 (46/0) | 0 |
6 (170A) | M/53 | 5.0 | Subclinical | 151 | 34 (34/0) | 3 |
7 (178A) | M/65 | 6.0 | Subclinical | 115 | 20 (4/16) | 0 |
8 (207A) | F/41 | 3.0 | Overt | 99 | 18 (16/2) | 0 |
9 (271A) | F/43 | 3.0 | Overt | 66 | 18 (13/5) | 0 |
10 (967A) | F/29 | 3.3 | Overt | 14 | 13 (8/5) | 0 |
11 (923A) | M/55 | 4.0 | Subclinical | 20 | 9 (6/3) | 14 |
12 (223A) | F/45 | NK | Overt | 120 | 4 (1/3) | 0 |
13 (1013A) | F/29 | 2.0 | Subclinical | 7 | 3 (2/1) | 0 |
14 (226A) | M/47 | 2.5 | Subclinical | 82 | 3 (1/2) | 0 |
15 (317A) | F/60 | 4.3 | Subclinical | 92 | 2 (2/0) | 0 |
Mean | 47.5 | 4.0 | 66.8 | 64.1 | 1.4 | |
SD | 12.3 | 2.5 | 42.6 | 91.3 | 3.7 | |
Median | 45.0 | 3.2 | 61.0 | 18 (13/3) | 0 |
NK indicates not known.
Overt or subclinical hypercortisolism according to previously described criteria [21].